WO2010125088A3 - Nanoparticle contrast agents for diagnostic imaging - Google Patents

Nanoparticle contrast agents for diagnostic imaging Download PDF

Info

Publication number
WO2010125088A3
WO2010125088A3 PCT/EP2010/055685 EP2010055685W WO2010125088A3 WO 2010125088 A3 WO2010125088 A3 WO 2010125088A3 EP 2010055685 W EP2010055685 W EP 2010055685W WO 2010125088 A3 WO2010125088 A3 WO 2010125088A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanoparticles
charged group
contrast agents
diagnostic imaging
functionalized
Prior art date
Application number
PCT/EP2010/055685
Other languages
French (fr)
Other versions
WO2010125088A2 (en
Inventor
Robert Edgar Colborn
Peter John Bonitatibus Jr.
Andrew Soliz Torres
Michael Ernest Marino
Matthew David Butts
Amit Kulkarni
Brian C. Bales
Bruce Allan Hay
Original Assignee
General Electric Company
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/431,884 external-priority patent/US20100278734A1/en
Priority claimed from US12/431,892 external-priority patent/US20100278748A1/en
Priority claimed from US12/431,899 external-priority patent/US20100278749A1/en
Application filed by General Electric Company, Ge Healthcare As filed Critical General Electric Company
Priority to JP2012507726A priority Critical patent/JP2012525350A/en
Priority to EP10718938A priority patent/EP2424574A2/en
Priority to CN201080030219.6A priority patent/CN102481381B/en
Publication of WO2010125088A2 publication Critical patent/WO2010125088A2/en
Publication of WO2010125088A3 publication Critical patent/WO2010125088A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1848—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a silane
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Compositions of nanoparticles functionalized with at least one net positively charged group and at least one net negatively charged group, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a coreand a shell. The shell comprises a plurality of silane moieties; at least one silane moiety of the plurality is functionalized with a net positively charged group and at least one silane moiety of the plurality is functionalized with a net negatively charged group.
PCT/EP2010/055685 2009-04-29 2010-04-28 Nanoparticle contrast agents for diagnostic imaging WO2010125088A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2012507726A JP2012525350A (en) 2009-04-29 2010-04-28 Nanoparticle contrast agents for diagnostic imaging
EP10718938A EP2424574A2 (en) 2009-04-29 2010-04-28 Nanoparticle contrast agents for diagnostic imaging
CN201080030219.6A CN102481381B (en) 2009-04-29 2010-04-28 Nanoparticle contrast agents for diagnostic imaging

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US12/431,884 US20100278734A1 (en) 2009-04-29 2009-04-29 Nanoparticle contrast agents for diagnostic imaging
US12/431,892 US20100278748A1 (en) 2009-04-29 2009-04-29 Nanoparticle contrast agents for diagnostic imaging
US12/431,884 2009-04-29
US12/431,899 US20100278749A1 (en) 2009-04-29 2009-04-29 Nanoparticle contrast agents for diagnostic imaging
US12/431,899 2009-04-29
US12/431,892 2009-04-29

Publications (2)

Publication Number Publication Date
WO2010125088A2 WO2010125088A2 (en) 2010-11-04
WO2010125088A3 true WO2010125088A3 (en) 2011-03-10

Family

ID=42782998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/055685 WO2010125088A2 (en) 2009-04-29 2010-04-28 Nanoparticle contrast agents for diagnostic imaging

Country Status (4)

Country Link
EP (1) EP2424574A2 (en)
JP (1) JP2012525350A (en)
CN (1) CN102481381B (en)
WO (1) WO2010125088A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110743022A (en) * 2012-08-23 2020-02-04 通用电气健康护理有限公司 Nanoparticle compositions for diagnostic imaging
US11353533B2 (en) 2016-02-24 2022-06-07 Ohio State Innovation Foundation Methods and devices for contrast agent magnetic resonance imaging
CA3066505A1 (en) * 2017-06-09 2018-12-13 Universite Claude Bernard Lyon 1 Method for synthesizing silica nanoparticles
US20190001001A1 (en) * 2017-07-03 2019-01-03 General Electric Company Drug design for application-dependent payload, controlled pharmacokinetic distribution, and renal clearance

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107818A2 (en) * 2004-04-30 2005-11-17 University Of Florida Nanoparticles and their use for multifunctional bioimaging
US20070122620A1 (en) * 2005-11-02 2007-05-31 General Electric Company Nanoparticle-based imaging agents for x-ray / computed tomography and methods for making same
WO2007146680A1 (en) * 2006-06-06 2007-12-21 Florida State University Research Foundation , Inc. Stabilized silica colloid
WO2009078924A2 (en) * 2007-12-06 2009-06-25 The Regents Of The University Of California Mesoporous silica nanoparticles for biomedical applications

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070140974A1 (en) * 2005-12-15 2007-06-21 General Electric Company Targeted nanoparticles for magnetic resonance imaging
JP2007269770A (en) * 2006-03-09 2007-10-18 Mitsubishi Chemicals Corp Functional magnetic super-nanoparticle and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107818A2 (en) * 2004-04-30 2005-11-17 University Of Florida Nanoparticles and their use for multifunctional bioimaging
US20070122620A1 (en) * 2005-11-02 2007-05-31 General Electric Company Nanoparticle-based imaging agents for x-ray / computed tomography and methods for making same
WO2007146680A1 (en) * 2006-06-06 2007-12-21 Florida State University Research Foundation , Inc. Stabilized silica colloid
WO2009078924A2 (en) * 2007-12-06 2009-06-25 The Regents Of The University Of California Mesoporous silica nanoparticles for biomedical applications

Also Published As

Publication number Publication date
WO2010125088A2 (en) 2010-11-04
CN102481381A (en) 2012-05-30
CN102481381B (en) 2014-12-17
JP2012525350A (en) 2012-10-22
EP2424574A2 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
WO2010076237A3 (en) Nanoparticle contrast agents for diagnostic imaging
WO2011063217A3 (en) Compositions comprising conductive particles with surface-modified nanoparticles covalently attached thereto, and methods of making
WO2012081904A3 (en) Nano wire and method for manufacturing the same
IL209625A (en) Use of nanoparticles or nanoparticle aggregates to prepare pharmaceutical compositions for destroying pre-malignant or malignant cells
WO2012061607A3 (en) Compositions comprising functionalized carbon-based nanostructures and related methods
WO2011017456A3 (en) Localized delivery of nanoparticles for therapeutic and diagnostic applications
WO2010013224A3 (en) Curcumin nanoparticles and methods of producing the same
WO2007124131A3 (en) Hybrid nanomaterials as multimodal imaging contrast agents
WO2009134389A9 (en) An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
PL2411408T3 (en) Soluble "heavy-chain only" antibodies
EP2506967A4 (en) Nanoparticle composition and methods of making the same
EP2045214A3 (en) Gold nanoparticle-halloysite nanotube and method of forming the same
IL215123A0 (en) Polymer-agent conjugates, particles, compositions, and related methods of use
WO2011091065A3 (en) Synthetic nanostructures including nucleic acids and/or other entities
WO2011053901A3 (en) Magnetic nanostructures as theranostic agents
WO2007141050A3 (en) Functionalized solid polymer nanoparticles for diagnostic and therapeutic applications
MX357227B (en) Lipid-based nanoparticles.
WO2013087734A3 (en) Functionalised silicon nanoparticles
WO2008007290A3 (en) Core-shell nanoparticles for thearapy and imaging purposes
WO2010125088A3 (en) Nanoparticle contrast agents for diagnostic imaging
WO2013059528A3 (en) Encapsulated diagnostics and therapeutics in nanoparticles-conjugated to tropic cells and methods for their use
EP3441467A3 (en) Biotin complexes for treatment and diagnosis of alzheimer's disease
WO2010062854A3 (en) Methods and compositions for using bleomycin-derivatized microbubbles
SG10201501606VA (en) Compounds, compositions, formulations and their uses in the treatment of diseases related to copper retention or hepatic disorders
WO2012013994A3 (en) Ph-dependent gradual release pharmaceutical composition

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080030219.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10718938

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010718938

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012507726

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE